MedTrace Logo

Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease

NCT01584986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2012-04-25

No results posted yet for this study

Summary

Regeneration of the occluded peripheral arteries by autologous stem cell therapy is an emerging treatment modality for no-option patients with peripheral artery disease (PAD). The purpose of this study was to assess safety and efficacy of ex vivo expanded, peripheral blood-derived, autologous angiogenic cell precursors (ACPs) in no-option PAD patients.

Conditions

  • Critical Limb Ischemia

Interventions

BIOLOGICAL

ACP injections

Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)

Sponsors & Collaborators

  • TheraVitae Ltd.

    collaborator INDUSTRY

  • Salus Ltd.

    lead INDUSTRY

Principal Investigators

  • György Acsády, DSc · Semmelweis University Department of Cardiovascular Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-04-30
Completion
2009-07-31

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01584986 on ClinicalTrials.gov